Refine by
Cardiac Patient Articles & Analysis
37 news found
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
Yet, the barriers to care are high with only 11% of patients who have OUD receiving the MOUD they need.2 Additionally, OUD relapse is common amongst patients. ...
“During our clinical study using the Bodyport Cardiac Scale, we found patients more engaged, and our clinical team better empowered to make timely, individualized treatment adjustments to get ahead of changes in a patient’s condition before they worsen. ...
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
A range of topics spanning from continuing to care for patients during a pandemic to screening for asymptomatic atrial fibrillation are available. Evidence illustrating how the Zio service has helped healthcare systems improve cardiac patient care can be found in the case studies section of the CRC. ...
The research shows that the two-week, artificial intelligence-powered Zio system doesn’t just aid in diagnosing afib in patients with a standard risk level, but also helps monitor higher-risk patients after cardiac and other procedures, potentially saving hospitals time, money and bed space. “We are excited that these new data ...
When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated ...
The other six SAEs which occurred in four subjects were judged to be related to the administration procedure, with none of those being unexpected nor resulting in patient death. “The administration of XC001 appears to have been well-tolerated at all tested doses,” said Nahush Mokadam, M.D., presenting author at AATS, Division Director, Cardiac ...
The published results showed statistically significant and clinically relevant evidence of CAP-1002’s ability to improve both skeletal and cardiac muscle function in patients in the latter stages of the disease. We have active sites that are currently screening patients for our Phase 3, HOPE-3 clinical trial and expect to enroll our first ...
FDA has granted Fast Track designation to LB1148 for two clinical indications: reduction of adhesions following abdominal or pelvic surgery and treatment of postoperative GI dysfunction in pediatric patients undergoing cardiac surgery. About Palisade Bio Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that aid ...
Approximately 80 percent of patients were non-ambulant, and all patients were on a stable regimen of steroids. ...
Hanover, Germany, March 2, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the expansion of its Scientific Advisory Board (SAB) with four newly appointed cardiology and RNA drug development experts. Johann Bauersachs, MD; Perry Elliott, ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. The Company believes that its wireless, ...
Hiring a skilled specialist such as MDA is key and the next step for Positron’s business to offer a state-of-the-art PET/CT device delivering the best images for cardiac patients and our future expected oncology customers.” ...
Food and Drug Administration (FDA) for its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients. ...
Their aim is that millions of immunosuppressed patients can use PointCheck™ for frequent testing, thus removing the need for a blood draw. ...
Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the schedule of presentations to be featured at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Orlando, Florida from November 4th to November 6th. The presentations include a spotlight on the ...
[Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina. ...